Novartis: signs license deal for three new antibiotics
(CercleFinance.com) - Swiss biopharmaceutical group Novartis has entered into a licensing agreement with privately owned Boston Pharmaceuticals for the development of three novel anti-infective drugs.
Under the terms of the deal, Boston Pharma has acquired worldwide rights to three candidates intended to treat antibiotic resistant Gram-negative infections.
In exchange, Novartis will receive an upfront payment and is entitled to royalties and milestone payments for successfully commercialised medicines, as well as an equity stake in two new companies formed to further develop and commercialise these programs.
Other financial terms were not disclosed.
Antibiotic resistance is recognised as a major public health threat, with drug resistant Pseudomonads being considered as a serious threat to human health.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Under the terms of the deal, Boston Pharma has acquired worldwide rights to three candidates intended to treat antibiotic resistant Gram-negative infections.
In exchange, Novartis will receive an upfront payment and is entitled to royalties and milestone payments for successfully commercialised medicines, as well as an equity stake in two new companies formed to further develop and commercialise these programs.
Other financial terms were not disclosed.
Antibiotic resistance is recognised as a major public health threat, with drug resistant Pseudomonads being considered as a serious threat to human health.
Copyright (c) 2018 CercleFinance.com. All rights reserved.